Which has higher valuation & earnings, ACHV or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Is ACHV or GPCR more profitable?

Structure Therapeutics' return on equity of -25.56% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% Structure Therapeutics N/A -25.56% -24.31%

Does the media prefer ACHV or GPCR?

In the previous week, Structure Therapeutics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Achieve Life Sciences. Structure Therapeutics' average media sentiment score of 0.51 beat Achieve Life Sciences' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or ACHV?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 1 mentions for Achieve Life Sciences. Arcutis Biotherapeutics' average media sentiment score of 0.46 beat Achieve Life Sciences' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ACHV or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is ACHV or MBX more profitable?

MBX Biosciences' return on equity of -26.02% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% MBX Biosciences N/A -26.02% -24.94%

Does the media refer more to ACHV or MBX?

In the previous week, MBX Biosciences had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Achieve Life Sciences. MBX Biosciences' average media sentiment score of 0.45 beat Achieve Life Sciences' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ACHV or MOR?

Achieve Life Sciences currently has a consensus price target of $15.00, suggesting a potential upside of 87.97%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Achieve Life Sciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Achieve Life Sciences (ACHV) Competitors

$7.98 +0.07 (+0.88%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.95 -0.03 (-0.40%)

As of 09/18/2026 07:55 PM Eastern

Compare

ACHV vs. GPCR, ARQT, MBX, MOR, and ATAI

Should you buy Achieve Life Sciences stock or one of its competitors? Achieve Life Sciences's main competitors and comparable companies include Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), MorphoSys (MOR), and Atai Beckley (ATAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Achieve Life Sciences compare to Structure Therapeutics?

Achieve Life Sciences (NASDAQ:ACHV) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Achieve Life Sciences presently has a consensus price target of $15.00, indicating a potential upside of 87.97%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 216.88%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Structure Therapeutics' return on equity of -25.56% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Structure Therapeutics	N/A	-25.56%	-24.31%

Achieve Life Sciences has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.45, suggesting that its share price is 245% less volatile than the broader market.

In the previous week, Structure Therapeutics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Achieve Life Sciences. Structure Therapeutics' average media sentiment score of 0.51 beat Achieve Life Sciences' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Summary

Structure Therapeutics beats Achieve Life Sciences on 9 of the 13 factors compared between the two stocks.

How does Achieve Life Sciences compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Arcutis Biotherapeutics has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.47	-$16.14M	$0.21	120.69
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

33.5% of Achieve Life Sciences shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Achieve Life Sciences' net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Arcutis Biotherapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 1 mentions for Achieve Life Sciences. Arcutis Biotherapeutics' average media sentiment score of 0.46 beat Achieve Life Sciences' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics presently has a consensus target price of $35.57, suggesting a potential upside of 40.35%. Achieve Life Sciences has a consensus target price of $15.00, suggesting a potential upside of 87.97%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Arcutis Biotherapeutics beats Achieve Life Sciences on 11 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to MBX Biosciences?

Achieve Life Sciences (NASDAQ:ACHV) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

MBX Biosciences' return on equity of -26.02% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
MBX Biosciences	N/A	-26.02%	-24.94%

In the previous week, MBX Biosciences had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Achieve Life Sciences. MBX Biosciences' average media sentiment score of 0.45 beat Achieve Life Sciences' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

33.5% of Achieve Life Sciences shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Achieve Life Sciences presently has a consensus target price of $15.00, indicating a potential upside of 87.97%. MBX Biosciences has a consensus target price of $77.00, indicating a potential upside of 22.40%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Achieve Life Sciences has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Summary

Achieve Life Sciences beats MBX Biosciences on 8 of the 14 factors compared between the two stocks.

How does Achieve Life Sciences compare to MorphoSys?

Achieve Life Sciences (NASDAQ:ACHV) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Achieve Life Sciences has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

In the previous week, Achieve Life Sciences had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Achieve Life Sciences and 0 mentions for MorphoSys. Achieve Life Sciences' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score.

Company	Overall Sentiment
Achieve Life Sciences	Neutral
MorphoSys	Neutral

Achieve Life Sciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Achieve Life Sciences' return on equity of -511.12% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
MorphoSys	-226.79%	-694.31%	-22.55%

Achieve Life Sciences has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Achieve Life Sciences currently has a consensus price target of $15.00, suggesting a potential upside of 87.97%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Achieve Life Sciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Achieve Life Sciences beats MorphoSys on 13 of the 15 factors compared between the two stocks.

How does Achieve Life Sciences compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Achieve Life Sciences has lower revenue, but higher earnings than Atai Beckley. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

In the previous week, Achieve Life Sciences had 1 more articles in the media than Atai Beckley. MarketBeat recorded 1 mentions for Achieve Life Sciences and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.00 equaled Achieve Life Sciences'average media sentiment score.

Company	Overall Sentiment
Atai Beckley	Neutral
Achieve Life Sciences	Neutral

Achieve Life Sciences has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Atai Beckley's return on equity of -88.30% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Atai Beckley presently has a consensus target price of $10.56, indicating a potential upside of 43.62%. Achieve Life Sciences has a consensus target price of $15.00, indicating a potential upside of 87.97%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Achieve Life Sciences beats Atai Beckley on 10 of the 15 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$821.16M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-5.15	653.41	214.59	20.89
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	19.95	10.53	10.46	6.33
Net Income	-$54.65M	$2.82B	$3.49B	$358.33M
7 Day Performance	13.03%	1.69%	0.59%	1.12%
1 Month Performance	-6.45%	0.83%	-2.01%	-2.67%
1 Year Performance	181.48%	3.90%	18.09%	6.01%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	2.1568 of 5 stars	$7.98 +0.9%	$15.00 +88.0%	+178.0%	$821.16M	N/A	N/A	28
GPCR Structure Therapeutics	2.5065 of 5 stars	$44.54 -5.9%	$110.91 +149.0%	+50.7%	$3.09B	N/A	N/A	136	Analyst Downgrade
ARQT Arcutis Biotherapeutics	3.626 of 5 stars	$24.29 +1.6%	$35.57 +46.4%	+43.1%	$3.05B	$376.07M	115.58	150	News Coverage
MBX MBX Biosciences	2.6118 of 5 stars	$63.04 +2.1%	$77.00 +22.2%	+524.7%	$3.04B	N/A	N/A	N/A
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. GPCR, ARQT, MBX, MOR, and ATAI

How does Achieve Life Sciences compare to Structure Therapeutics?

Summary

How does Achieve Life Sciences compare to Arcutis Biotherapeutics?

Summary

How does Achieve Life Sciences compare to MBX Biosciences?

Summary

How does Achieve Life Sciences compare to MorphoSys?

Summary

How does Achieve Life Sciences compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. GPCR, ARQT, MBX, MOR, and ATAI

How does Achieve Life Sciences compare to Structure Therapeutics?

Do institutionals & insiders have more ownership in ACHV or GPCR?

Do analysts rate ACHV or GPCR?

Is ACHV or GPCR more profitable?

Which has more volatility and risk, ACHV or GPCR?

Does the media prefer ACHV or GPCR?

Which has higher valuation & earnings, ACHV or GPCR?

Summary

How does Achieve Life Sciences compare to Arcutis Biotherapeutics?

Which has preferable earnings & valuation, ARQT or ACHV?

Do insiders and institutionals believe in ARQT or ACHV?

Is ARQT or ACHV more profitable?

Which has more volatility & risk, ARQT or ACHV?

Does the media favor ARQT or ACHV?

Do analysts recommend ARQT or ACHV?

Summary

How does Achieve Life Sciences compare to MBX Biosciences?

Is ACHV or MBX more profitable?

Does the media refer more to ACHV or MBX?

Which has better earnings and valuation, ACHV or MBX?

Do insiders and institutionals believe in ACHV or MBX?

Do analysts recommend ACHV or MBX?

Which has more volatility and risk, ACHV or MBX?

Summary

How does Achieve Life Sciences compare to MorphoSys?

Do insiders and institutionals have more ownership in ACHV or MOR?

Which has more risk & volatility, ACHV or MOR?

Does the media refer more to ACHV or MOR?

Is ACHV or MOR more profitable?

Which has higher valuation & earnings, ACHV or MOR?

Do analysts recommend ACHV or MOR?

Summary

How does Achieve Life Sciences compare to Atai Beckley?

Do insiders & institutionals have more ownership in ATAI or ACHV?

Which has more risk & volatility, ATAI or ACHV?

Which has higher valuation and earnings, ATAI or ACHV?

Does the media favor ATAI or ACHV?

Is ATAI or ACHV more profitable?

Do analysts rate ATAI or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools